Welcome to our dedicated page for Edesa Biotech SEC filings (Ticker: EDSA), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
Edesa Biotech filings document the formal disclosure record of a clinical-stage biotechnology issuer focused on host-directed therapeutics for immuno-inflammatory diseases. Recent Form 8-K reports cover clinical-study disclosures for paridiprubart in Acute Respiratory Distress Syndrome, operating and financial results, material-event updates and agreements connected to funded development work.
The company’s filings also address capital-structure matters, including common-share sales under at-the-market offering arrangements and related Form S-3 prospectus supplements. Proxy materials cover shareholder voting matters, board governance, executive compensation and equity-award disclosures for the public company.
Nijhawan Pardeep reported acquisition or exercise transactions in this Form 4 filing.
Edesa Biotech, Inc. Chief Executive Officer and 10% owner Pardeep Nijhawan received a grant of 5,324 restricted share units on 2026-08-03, vesting in full upon grant under the 2019 Equity Incentive Compensation Plan. After this award, he directly holds 893,386 common shares, plus additional indirect holdings through affiliated entities and a family trust, for which he disclaims beneficial ownership beyond his pecuniary interest.
Edesa Biotech, Inc. is registering up to 729,241 common shares for resale by existing investors who acquired these shares in a June 2026 private placement. This is a resale registration only; Edesa will not receive any proceeds from sales made under this prospectus, though it has borne the registration costs.
In the private placement, institutional and accredited investors, including the chief executive officer, purchased an aggregate of $3.5 million of common shares at $4.69 per share for outside investors and $5.21 per share for the CEO. Edesa previously stated it intends to use those net proceeds to advance its vitiligo program and its respiratory drug candidate paridiprubart, and for working capital and general corporate purposes.
Edesa is a biopharmaceutical company focused on inflammatory and immune-related diseases, with programs in medical dermatology (including vitiligo and allergic contact dermatitis) and respiratory conditions such as acute respiratory distress syndrome. As of June 17, 2026, it had 9,633,223 common shares outstanding and listed its common shares on the Nasdaq Capital Market under the symbol EDSA.
Nijhawan Pardeep reported acquisition or exercise transactions in this Form 4 filing.
Edesa Biotech Chief Executive Officer Pardeep Nijhawan reported a compensation-related stock grant. He received 3,378 restricted share units of Edesa Biotech common shares at no cost, which vested in full upon grant under the company’s 2019 Equity Incentive Compensation Plan.
Following this award, he directly holds 888,062 common shares. The filing also lists indirect common share holdings held through entities such as Pardeep Nijhawan Medicine Professional Corporation, 1968160 Ontario Inc., The Digestive Health Clinic Inc., and The New Nijhawan Family Trust 2015, for which he reports positions but disclaims full beneficial ownership beyond his pecuniary interest.
Edesa Biotech, Inc. registers for resale up to 729,241 common shares issued in a private placement closed June 16, 2026.
The prospectus states these Shares were sold at $4.69 per share to Purchasers (and $5.21 per share to the CEO) for aggregate proceeds of approximately $3.5 million, and that the Company will not receive any proceeds from subsequent resales. Shares outstanding were 9,633,223 as of June 17, 2026.
Edesa Biotech, Inc. Schedule 13G shows a group of related filers including Integrated Core Strategies (US) LLC, Millennium Management LLC, Millennium Group Management LLC and Israel A. Englander reporting shared beneficial ownership of 520,685 shares, equal to 5.4% of the company’s common stock. The filing bases the percent on 9,621,192 Common Shares outstanding, composed of 8,891,951 shares as of May 13, 2026 and 729,241 shares issued in a private placement that closed on or about June 15, 2026. The filing is a joint filing under a Joint Filing Agreement dated June 17, 2026 and describes shared voting and dispositive power rather than sole control.
Dr. Pardeep Nijhawan has filed Amendment No. 10 to his Schedule 13D for Edesa Biotech, Inc., updating his ownership in the company’s common shares. As of June 16, 2026, he may be deemed the beneficial owner of 2,210,022 common shares, representing approximately 19.99% of Edesa’s outstanding common shares on an as‑converted, as‑exercised basis.
His position includes 927,620 shares over which he has sole voting and dispositive power, and 1,282,402 shares over which he has shared power through several affiliated entities. The amendment reflects multiple restricted stock unit grants in 2025–2026, open‑market purchases in March 2026, and a June 16, 2026 private placement purchase of 153,550 shares at $5.21 per share for a total of $799,995.50.
The filing notes a 19.99% beneficial ownership blocker on certain Series B‑1 preferred shares, which limits further conversions that would push his ownership above that threshold.
Edesa Biotech, Inc. Chief Executive Officer Pardeep Nijhawan acquired additional common shares in a private transaction. On June 16, 2026, he purchased 153,550 common shares at $5.21 per share, for a total of $799,995.50, and now directly holds 884,684 common shares.
He also has indirect holdings through several entities and a family trust, where he disclaims beneficial ownership beyond his pecuniary interest. These structures mean some shares are legally held by corporations and a trust associated with him rather than in his own name.
Edesa Biotech, Inc. entered into a securities purchase agreement for a private placement of approximately $3.5 million of common shares. The company plans to sell 729,241 shares in a PIPE financing, at $4.69 per share for investors and $5.21 per share for its Chief Executive Officer.
The closing is expected on June 15, 2026, subject to customary conditions. Edesa expects to use the net proceeds to advance its vitiligo program, its drug candidate paridiprubart, and for working capital and general corporate purposes. A Registration Rights Agreement requires Edesa to file one or more resale registration statements with the SEC within 45 days of closing.
Edesa Biotech reported new exploratory subgroup data for paridiprubart, its anti-TLR4 antibody, in critically ill patients with acute kidney injury and respiratory distress. Analyses pooling Phase 2 and Phase 3 studies created a 101-patient AKI subgroup from a broader 278-patient population with acute respiratory distress syndrome.
Paridiprubart plus standard of care was associated with adjusted 28-day mortality of 33% versus 49% for placebo, a 32% relative reduction in risk of death, and reduced major adverse kidney events (MAKE30) to 41% versus 53%, with nominal p<0.005 for both endpoints. Safety in the AKI subgroup remained consistent with more than 400 patients treated to date.
The company emphasizes that these AKI findings are exploratory, were not prespecified, use multivariate logistic regression, and are intended to generate hypotheses. Confirmatory studies would be required to establish efficacy in AKI, though the results support ongoing ARDS development and potential future AKI-focused trials.